Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 10,845 Shares

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 10,845 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $41,536.35. Following the transaction, the chief financial officer now directly owns 471,727 shares in the company, valued at $1,806,714.41. The trade was a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Stephen Furlong also recently made the following trade(s):

• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Price Performance

Shares of STIM opened at $4.36 on Friday. The stock’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $1.42. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in STIM. Tradewinds LLC. bought a new position in shares of Neuronetics in the 4th quarter worth about $32,000. XTX Topco Ltd bought a new position in shares of Neuronetics in the 4th quarter worth about $49,000. Landscape Capital Management L.L.C. bought a new position in shares of Neuronetics in the 3rd quarter worth about $53,000. GSA Capital Partners LLP raised its position in shares of Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares in the last quarter. Finally, David J Yvars Group raised its position in shares of Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after acquiring an additional 14,825 shares in the last quarter. 53.59% of the stock is owned by institutional investors.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.